Benefit-risk assessment of mRNA COVID-19 vaccines in children aged 6 months to 4 years in the Omicron era
Description
CONCLUSIONS: The expected benefit of receiving the primary series of mRNA vaccines outweighed the risk among children ages 6 months to 4 years regardless of sex, presence of underlying medical conditions, presence of infection-induced immunity or
